

FOR IMMEDIATE RELEASE

Lee's Pharmaceutical successfully obtained the Imported Drug License for MICTONORM® in China

Hong Kong, 12 November 2014 - Lee's Pharmaceutical Holdings Limited (the "Group" or "Lee's") (Main Board Stock Code: 0950; Website: www.leespharm.com) announced today that the Group has successfully obtained an Import Drug License (IDL No. H20140799) from the China FDA to import and market Mictonorm® - Propiverine Hydrochloride 30 mg Capsules - in China.

Mictonorm® is for oral use and contains Propiverine Hydrochloride as its active ingredient. Propiverine belongs to the anticholinergic or antimuscarinic muscle relaxant class and is one of the most frequently prescribed drugs for the treatment of unstable bladder conditions and urinary incontinence. It works by relaxing the involuntary muscle that is found in the wall of the bladder by blocking the cholinergic or muscarinic receptors located on the surface of the muscle cells. Although oxybutynin is the most widely used drug on the market for bladder instability, propiverine, a newer agent available for the treatment of urinary incontinence, has a better tolerability than oxybutynin, especially with regard to dryness of the mouth.

Urinary incontinence is a common condition, particularly in women, in the elderly and in patients with neurological diseases. It may cause considerable disruption to sufferers' quality of life yet many cases may be cured or significantly improved with appropriate treatment. Approvals for propiverine have been issued in numerous countries in Europe (including Germany, the United Kingdom, Turkey, Italy, Croatia, Czech Republic and Slovakia) and Asia (including Japan and South Korea). In Japan, the sales for Mictonorm® have reached a substantial level with a significant market share achieved by the product in a relatively short period of time. The Group is well positioned to successfully penetrate this market segment with growing demands in China.

"We're extremely excited about the obtainment of this Imported Drug License," stated Dr. Benjamin Li, Chief Executive Officer of the Group. "On the heel of two approvals of Imported Drug License last year, this achievement reaffirms the Group's ability and capability in drug development in China. The strong pipeline of the Group is the pivotal to the continued growth of the Company. We expect to launch the product by the 2nd quarter of next year. Mictonorm® will certainly broaden the Group's revenue base."

FOR IMMEDIATE RELEASE

About Apogepha

Founded in Dresden, Germany in 1882, APOGEPHA Arzneimittel GmbH presents itself today as a highly competitive independent pharmaceutical company. APOGEPHA is a medium-sized pharmaceutical company specializing in the field of urology, with its own production facilities. APOGEPHA developed propiverine, one of the leading drugs for the treatment of overactive bladder and neurogenic detrusor overactivity in adults and children. Various dosages and formulations of propiverine are available under the trademarks **Mictonorm**[®] and **Detrunorm**[®]. The patent of its unique once daily formulation of propiverine is approved in most countries. Currently APOGEPHA has marketing and distribution partners in more than twenty countries, with a focus on Europe, Middle East and Asia. Additional information about APOGEPHA is available at www.apogepha.com.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, urology, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: +852 2314-1282

Fax: +852 2314-1708

Email: info@leespharm.com